Document is current
Any future updates will be listed below
-
Authors
van Lent, Liza G. G. http://orcid.org/0000-0002-4979-3051
van der Ham, Mirte http://orcid.org/0000-0002-7094-7510
de Jonge, Maja J. A. http://orcid.org/0000-0002-1938-226X
Gort, Eelke H. http://orcid.org/0000-0001-7390-0761
van Mil, Marjolein
Hasselaar, Jeroen http://orcid.org/0000-0002-8880-2029
van der Rijt, Carin C. D. http://orcid.org/0000-0001-5996-1242
van Gurp, Jelle http://orcid.org/0000-0002-9904-2571
van Weert, Julia C. M. http://orcid.org/0000-0002-2259-5864
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (KWF11086)
- License Information
-
More Information
Article History
Received: 6 June 2023
Accepted: 22 January 2024
First Online: 2 February 2024
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. The Medical Ethics Committee of the Erasmus MC (Rotterdam, The Netherlands), has reviewed the research proposal for the entire project (of which the study reported here is a part) and assessed that the rules laid down in the Medical Research Involving Human Subjects Act, do not apply (MEC-2018–151). Research governance approval was received from all participating hospitals. Patients provided written informed consent before their consultation was recorded. Additionally, all (fellow) medical oncologists whose consultations were recorded provided written informed consent before their first consultation was recorded.
: Not applicable.
: CR has received the grant from Dutch Cancer Society for the conduct of the study; and a personal fee from Kyowa Kirin BV and Ipsen Pharmaceutica BV (both outside the submitted work). The other authors declare that they have no competing interests.
